Received Jul 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | OT |
HCP called and reported missed doses for VARIVAX and MMR-II.; No additional AE; first dose of VARIVAX on 16NOV2024 and their first dose of MMR-II on 11NOV2024; This spontaneous report was received from a medical student and refers to a 55-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 11-Nov-2024, the patient was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), solution for injection, the vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (dose, route of administration, lot # and expiration date were not reported), administered as prophylaxis. Afterwards, on 16-Nov-2024, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), solution for injection, the vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (dose, route of administration, lot # and expiration date were not reported), administered as prophylaxis (Inappropriate schedule of product administration). On an unknown date, the patient missed doses for Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) and Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (Product dose omission issue). No adverse event. Batch/Lot number is being requested and will be submitted if received.
Sterile diluent